BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

...and other KRAS mutations. The most advanced is an RNAi therapy against KRAS G12D from Silenseed Ltd....
BioCentury | Oct 5, 2015
Finance

Volatile, not futile

...$52M Pivotal Anterios Inc. 3/31/15 $50.7M Ph II Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Silenseed Ltd....
BioCentury | Jul 13, 2015
Finance

Tiers, some fears

...Diagnostics Inc. 9/19/14 Up to $69M Mkt (diagnostic) rEVO Biologics Inc. 6/25/14 $50.4M Mkt (drug) Silenseed Ltd....
BioCentury | Apr 6, 2015
Finance

Fundamental rally

...Holdings Inc. 6/24/14 TBD Mkt (diagnostic) Ark Animal Health Inc. (E) 6/23/14 TBD Development (vet) Silenseed Ltd....
BioCentury | Jan 5, 2015
Finance

2015 Financial Markets Preview: Show me in 2015

...Animal Health Inc. (E) 6/23/14 TBD Development (vet) Tobira Therapeutics Inc. 6/23/14 TBD Ph II Silenseed Ltd....
BioCentury | Oct 6, 2014
Finance

4Q14 Financial Markets Preview: 'Perfect world' - for now

...Biotherapeutics Inc. 6/20/14 $75M Ph II Q Therapeutics Inc. (OTCBB) 6/20/13 Up to $5M Preclin Silenseed Ltd....
BioCentury | Jul 24, 2014
Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Discerning optimism

...Innocoll GmbH 6/19/14 Up to $86.3M Mkt (device) Sage Therapeutics Inc. 6/17/14 $60M Ph I/II Silenseed Ltd....
BioCentury | Jun 23, 2014
Financial News

Silenseed proposes IPO

Silenseed Ltd. , Jerusalem, Israel Business: Cancer Date announced: 2014-06-13 Type: IPO To be raised: Up to $36.4 million Price: TBD Underwriter: Aegis Capital Note: The company is seeking to list its shares on NASDAQ. WIR...
BioCentury | Jun 19, 2014
Financial News

Cancer company Silenseed files for IPO

Silenseed Ltd. (Jerusalem, Israel) filed to raise up to $36.4 million in an IPO on NASDAQ underwritten by Aegis. Silenseed is using its LODER drug delivery system -- a miniature biodegradable polymeric matrix that is...
Items per page:
1 - 10 of 12
BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

...and other KRAS mutations. The most advanced is an RNAi therapy against KRAS G12D from Silenseed Ltd....
BioCentury | Oct 5, 2015
Finance

Volatile, not futile

...$52M Pivotal Anterios Inc. 3/31/15 $50.7M Ph II Exagen Diagnostics Inc. 9/19/14 TBD Mkt (diagnostic) Silenseed Ltd....
BioCentury | Jul 13, 2015
Finance

Tiers, some fears

...Diagnostics Inc. 9/19/14 Up to $69M Mkt (diagnostic) rEVO Biologics Inc. 6/25/14 $50.4M Mkt (drug) Silenseed Ltd....
BioCentury | Apr 6, 2015
Finance

Fundamental rally

...Holdings Inc. 6/24/14 TBD Mkt (diagnostic) Ark Animal Health Inc. (E) 6/23/14 TBD Development (vet) Silenseed Ltd....
BioCentury | Jan 5, 2015
Finance

2015 Financial Markets Preview: Show me in 2015

...Animal Health Inc. (E) 6/23/14 TBD Development (vet) Tobira Therapeutics Inc. 6/23/14 TBD Ph II Silenseed Ltd....
BioCentury | Oct 6, 2014
Finance

4Q14 Financial Markets Preview: 'Perfect world' - for now

...Biotherapeutics Inc. 6/20/14 $75M Ph II Q Therapeutics Inc. (OTCBB) 6/20/13 Up to $5M Preclin Silenseed Ltd....
BioCentury | Jul 24, 2014
Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Discerning optimism

...Innocoll GmbH 6/19/14 Up to $86.3M Mkt (device) Sage Therapeutics Inc. 6/17/14 $60M Ph I/II Silenseed Ltd....
BioCentury | Jun 23, 2014
Financial News

Silenseed proposes IPO

Silenseed Ltd. , Jerusalem, Israel Business: Cancer Date announced: 2014-06-13 Type: IPO To be raised: Up to $36.4 million Price: TBD Underwriter: Aegis Capital Note: The company is seeking to list its shares on NASDAQ. WIR...
BioCentury | Jun 19, 2014
Financial News

Cancer company Silenseed files for IPO

Silenseed Ltd. (Jerusalem, Israel) filed to raise up to $36.4 million in an IPO on NASDAQ underwritten by Aegis. Silenseed is using its LODER drug delivery system -- a miniature biodegradable polymeric matrix that is...
Items per page:
1 - 10 of 12